2016 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/12/16UroGen Pharma Announces FDA Acceptance of Investigational New Drug Application for MitoGel, a Novel Sustained Release Formulation of Mitomycin C, for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma
-Plans to Initiate Single Pivotal, Open-Label, Single-Arm Phase 3 Clinical Trial in First Quarter of 2017- Ra'anana, Israel, New York, NY, December 12, 2016: UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company, today announced the acceptance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for MitoGel™ for the treatment of low-grade upper tract urothelial carcinoma (UTUC).  There are currently no FDA-approved drugs ... 
Printer Friendly Version
10/04/16UroGen Pharma Announces Agreement to License RTGel™ for Use with Neurotoxins to Allergan
RAANANA, Israel, Oct. 14, 2016 — UroGen Pharma ("UroGen"), a privately-held, clinical-stage biotechnology company,  announced today that it has completed an agreement to license worldwide rights to UroGen's RTGelTM delivery system technology for use with neurotoxins to Allergan plc. RTGel™ has thermo-sensitive properties that enable it to convert from a liquid state when cold, into a gel once it reaches body temperature. This allows increased residence time of drugs when mixed with the gel... 
Printer Friendly Version
05/05/16UroGen Pharma Announces Three Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association’s 2016 Annual Meeting
New York, NY and Ra'anana, Israel, May 5, 2016: UroGen Pharma, a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with a focus on uro-oncology, announced today that the Company has been selected to present two oral/podium presentations and one poster presentation at the American Urology Association 2016 Annual Meeting in San Diego, California, on May 7-11, 2016.“We are excited that findings from three studies... 
Printer Friendly Version
02/08/16UroGen Pharma Strengthens Board of Directors and Senior Management Team
Appoints Stuart Holden, M.D., to its Board of Directors and Mark Schoenberg, M.D., as Medical Director New York, NY and Ra'anana, Israel, February 8, 2016: UroGen Pharma, Ltd. a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with a focus on uro-oncology, announced today the appointment of Stuart Holden, M.D., to its Board of Directors and the addition of Mark Schoenberg, M.D., as Medical Director.Dr. Stuart Hold... 
Printer Friendly Version
01/13/16UroGen Pharma Strengthens Leadership Team and Expands Uro-Oncology Clinical Pipeline with Addition of TLR-7 Agonist Phase 2 Asset
New York, NY and Ra'anana, Israel, January 13, 2016: UroGen Pharma, Ltd. (formerly known as TheraCoat), a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for urological pathologies with a focus on uro-oncology, announced today the appointment of two key executive officers: Ron Bentsur has joined the company as Chief Executive Officer and Gary Titus has joined the company as Chief Financial Officer.  In addition, Gil Hakim has been app... 
Printer Friendly Version